Characteristics of alloreactive T cells measured before renal transplantation

Clinical and Experimental Immunology

Volumn 168, Issue 2, 2012, Pages 241-250

  van de Berg, P J E J ^a   Yong, S L ^a   Koch, S D ^a   Lardy, N ^b   van Donselaar van der Pant, K A M I ^a   Florquin, S ^a   Bemelman, F J ^a   van Lier, R A W ^a   ten Berge, I J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Sanquin Diagnostiek   (Netherlands)

Author keywords

Alloreactivity; IL7R ; Kidney; Rejection; T cell

Indexed keywords

BASILIXIMAB; CARBOXYFLUORESCEIN DIACETATE SUCCINIMIDYL ESTER; CHEMOKINE RECEPTOR; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR ALPHA; MYCOPHENOLIC ACID; PREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; ALLOIMMUNITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CLINICAL ARTICLE; CYTOMETRY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; MALE; MIXED LYMPHOCYTE CULTURE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOPHENOTYPING; INTERFERON-GAMMA; INTERLEUKIN-15 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE TEST, MIXED; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE; RECEPTORS, CYTOKINE; RECEPTORS, INTERLEUKIN-7; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859224206     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04551.x     Document Type: Article

References (38)

1. Bestard O, Nickel P, Cruzado JM etal. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19:1419-29.
2. van Besouw NM, van der Mast BJ, de KP etal. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 2000; 70:136-43.
3. Augustine JJ, Poggio ED, Heeger PS, Hricik DE. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation 2008; 86:529-34.
4. Nickel P, Presber F, Bold G etal. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renal-transplant recipients. Transplantation 2004; 78:1640-6.
5. Poggio ED, Augustine JJ, Clemente M etal. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007; 83:847-52.
6. Brook MO, Wood KJ, Jones ND. The impact of memory T cells on rejection and the induction of tolerance. Transplantation 2006; 82:1-9.
7. Dinavahi R, Heeger PS. T-cell immune monitoring in organ transplantation. Curr Opin Organ Transplant 2008; 13:419-24.
8. Sawitzki B, Pascher A, Babel N, Reinke P, Volk HD. Can we use biomarkers and functional assays to implement personalized therapies in transplantation? Transplantation 2009; 87:1595-601.
9. Poggio ED, Clemente M, Riley J etal. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 2004; 15:1952-60.
10. Ito T, Ueno T, Clarkson MR etal. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo. J Immunol 2005; 174:6648-56.
11. Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999; 162:1947-51.
12. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338:1813-21.
13. Alves NL, van Leeuwen EM, Derks IA, van Lier RA. Differential regulation of human IL-7 receptor alpha expression by IL-7 and TCR signaling. J Immunol 2008; 180:5201-10.
14. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003; 3:269-79.
15. Hancock WW, Wang L, Ye Q, Han R, Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003; 15:479-86.
16. Panzer U, Reinking RR, Steinmetz OM etal. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. Transplantation 2004; 78:1341-50.
17. Schaub S, Nickerson P, Rush D etal. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009; 9:1347-53.
18. Tatapudi RR, Muthukumar T, Dadhania D etal. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65:2390-7.
19. Wever PC, Boonstra JG, Laterveer JC etal. Mechanisms of lymphocyte-mediated cytotoxicity in acute renal allograft rejection. Transplantation 1998; 66:259-64.
20. Uss E, Rowshani AT, Hooibrink B, Lardy NM, van Lier RA, ten Berge IJ. CD103 is a marker for alloantigen-induced regulatory CD8+ T cells. J Immunol 2006; 177:2775-83.
21. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3:199-210.
22. Nikolaeva N, Uss E, van Leeuwen EM, van Lier RA, ten Berge IJ. Differentiation of human alloreactive CD4+ and CD8+ T cells in vitro. Transplantation 2004; 78:815-24.
23. Sis B, Mengel M, Haas M etal. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010; 10:464-71.
24. Gaber LW, Moore LW, Alloway RR etal. Correlation between Banff classification, acute renal rejection scores and reversal of rejection. Kidney Int 1996; 49:481-7.
25. He X, Janeway CA, Jr, Levine M etal. Dual receptor T cells extend the immune repertoire for foreign antigens. Nat Immunol 2002; 3:127-34.
26. Gebauer BS, Hricik DE, Atallah A etal. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2:857-66.
27. Bacchetta R, Passerini L, Gambineri E etal. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest 2006; 116:1713-22.
28. Ruiz P, Fuller J, Sanfilippo F. Donor-specific cellular immunity in rejecting and long-term-surviving class I-disparate rat renal allograft recipients. Transplantation 1990; 49:175-83.
29. Dankers MK, Roelen DL, Korfage N etal. Differential immunogenicity of paternal HLA class I antigens in pregnant women. Hum Immunol 2003; 64:600-6.
30. Alves NL, van Leeuwen EM, Remmerswaal EB etal. A new subset of human naive CD8+ T cells defined by low expression of IL-7R alpha. J Immunol 2007; 179:221-8.
31. van Leeuwen EM, de Bree GJ, Remmerswaal EB etal. IL-7 receptor alpha chain expression distinguishes functional subsets of virus-specific human CD8+ T cells. Blood 2005; 106:2091-8.
32. Gregory SG, Schmidt S, Seth P etal. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39:1083-91.
33. Hafler DA, Compston A, Sawcer S etal. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357:851-62.
34. Shamim Z, Ryder LP, Heilmann C etal. Genetic polymorphisms in the genes encoding human interleukin-7 receptor-alpha: prognostic significance in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37:485-91.
35. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003; 4:1191-8.
36. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci USA 2004; 101:16004-9.
37. Cellerai C, Perreau M, Rozot V, Enders FB, Pantaleo G, Harari A. Proliferation capacity and cytotoxic activity are mediated by functionally and phenotypically distinct virus-specific CD8 T cells defined by interleukin-7R{alpha} (CD127) and perforin expression. J Virol 2010; 84:3868-78.
38. Racape M, Vanhove B, Soulillou JP, Brouard S. Interleukin 7 receptor alpha as a potential therapeutic target in transplantation. Arch Immunol Ther Exp (Warsz) 2009; 57:253-61.